Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03313206
Title Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (IMMUQ)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

mucosal melanoma

Therapies

Pembrolizumab

Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.